Sanofi/Organon Arixtra

Executive Summary

Arixtra added to 425 hospital formularies in the U.S. and Europe as of July, Sanofi says. Sanofi/Organon launched Arixtra (fondaparinux) for deep vein thrombosis in the first quarter (1"The Pink Sheet" Dec. 17, 2001, p. 3). While Arixtra sales had a slow start in the first half, "formulary wins are in line with expectations," Sanofi said. The company expects Arixtra to gain full access to the low molecular weight heparin market in 2006; Sanofi estimates its approved use in hospital-based orthopedic surgery provides 14% access...